These investigations focused on the impact of various SGLT2 inhibitors, including Dapagliflozin, Sotagliflozin, Canagliflozin, Ertugliflozin, Licogliflozin, Empagliflozin, and Luseogliflozin, in individuals with both chronic HF and T2DM. Here, SLC5A2 is linked to type 2 diabetes mellitus.